113 related articles for article (PubMed ID: 37997857)
1. Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner.
Bao Y; Wu X; Kanematsu A; Kita Y; Kobayashi T; Kakehi Y; Yamamoto S
Oncol Rep; 2024 Jan; 51(1):. PubMed ID: 37997857
[TBL] [Abstract][Full Text] [Related]
2. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
4. Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array.
Jin X; Wu XX; Jin C; Inui M; Sugimoto M; Kakehi Y
Anticancer Drugs; 2012 Apr; 23(4):445-54. PubMed ID: 22205156
[TBL] [Abstract][Full Text] [Related]
5. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of death receptor 4-mediated apoptosis and cytotoxicity in renal cell carcinoma cells by anisomycin.
Li Y; Wu X; Jin X; Wang J; Togo Y; Suzuki T; Hashimoto T; Yamada Y; Nakanishi Y; Kanematsu A; Nojima M; Kakehi Y; Yamamoto S
Anticancer Drugs; 2017 Feb; 28(2):180-186. PubMed ID: 27879498
[TBL] [Abstract][Full Text] [Related]
7. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors.
Sung B; Park B; Yadav VR; Aggarwal BB
J Biol Chem; 2010 Apr; 285(15):11498-507. PubMed ID: 20154087
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of human renal cell carcinoma cell lines to TRAIL-induced apoptosis by anthracyclines.
Wu XX; Ogawa O; Kakehi Y
Int J Urol; 2004 Mar; 11(3):164-70. PubMed ID: 15009365
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
[TBL] [Abstract][Full Text] [Related]
11. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study.
Li HY; Zhang J; Sun LL; Li BH; Gao HL; Xie T; Zhang N; Ye ZM
Cell Death Dis; 2015 Jan; 6(1):e1604. PubMed ID: 25611379
[TBL] [Abstract][Full Text] [Related]
12. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways.
Kannaiyan R; Manu KA; Chen L; Li F; Rajendran P; Subramaniam A; Lam P; Kumar AP; Sethi G
Apoptosis; 2011 Oct; 16(10):1028-41. PubMed ID: 21786165
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.
Zeng Y; Wu XX; Fiscella M; Shimada O; Humphreys R; Albert V; Kakehi Y
Int J Oncol; 2006 Feb; 28(2):421-30. PubMed ID: 16391797
[TBL] [Abstract][Full Text] [Related]
14. Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL‑induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species.
Nazim UM; Yin H; Park SY
Mol Med Rep; 2019 Feb; 19(2):984-993. PubMed ID: 30569150
[TBL] [Abstract][Full Text] [Related]
15. Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.
Fan XX; Li N; Wu JL; Zhou YL; He JX; Liu L; Leung EL
Molecules; 2014 Mar; 19(3):3508-22. PubMed ID: 24662070
[TBL] [Abstract][Full Text] [Related]
16. Celastrol, a plant-derived triterpene, induces cisplatin-resistance nasopharyngeal carcinoma cancer cell apoptosis though ERK1/2 and p38 MAPK signaling pathway.
Hsieh MJ; Wang CW; Lin JT; Chuang YC; Hsi YT; Lo YS; Lin CC; Chen MK
Phytomedicine; 2019 May; 58():152805. PubMed ID: 31022663
[TBL] [Abstract][Full Text] [Related]
17. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
Zhang L; Zhang X; Barrisford GW; Olumi AF
Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
[TBL] [Abstract][Full Text] [Related]
18. Celastrol Inhibits the Proliferation and Induces Apoptosis of Colorectal Cancer Cells via Downregulating NF-κB/COX-2 Signaling Pathways.
Zhang H; Zhao X; Shang F; Sun H; Zheng X; Zhu J
Anticancer Agents Med Chem; 2022; 22(10):1921-1932. PubMed ID: 34732120
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
20. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
